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Nearly 50% of women experience at least one urinary tract infection (UTI) in their lifetime. Studies with mice
have revealed that uropathogenic Escherichia coli (UPEC) isolates invade superficial umbrella cells that line
the bladder, allowing them to find a safe haven and subvert clearance by innate host responses. Rapid
intracellular replication results in the formation of distinctive intracellular bacterial communities (IBCs). In
this study, we evaluated whether UPEC strains cultured from the urine of women and classified as causing
acute cystitis, recurrent cystitis, asymptomatic bacteriuria, or pyelonephritis could progress through the IBC
cascade in a well-characterized mouse model of cystitis. Of 18 UPEC isolates collected from women, 15 formed
IBCs. Variations in the size, number, and kinetics of IBC formation were observed with strains isolated from
women with different clinical syndromes. Two of the three isolates that did not form IBCs when inoculated
alone were able to do so when coinoculated with an isolate that was capable of generating IBCs. The mixed
infections dramatically altered the behavior of the coinfecting bacteria relative to their behavior in a single
infection. The study also showed that mice with five different genetic backgrounds can support IBC formation.
Although UPEC isolates differ genetically in their virulence factors, the majority of UPEC isolates from
different types of UTI proceed through the IBC pathway, confirming the generality of IBCs in UTI pathogenesis
in mice.
Urinary tract infections (UTIs) account for nearly 7 million
office visits per year in the United States and cost $2 billion
annually (4). The majority of community-acquired UTIs occur
in women and are caused by uropathogenic Escherichia coli
(UPEC) (7). More than 40% of women who experience acute
cystitis develop recurrent UTIs (rUTIs) (12). Uropathogens
causing UTIs as well as asymptomatic bacteriuria (ASB) are
generally thought to emanate from the distal gut, colonize the
vagina, and ascend to the bladder via the urethra (4). Likewise,
acute pyelonephritis is assumed to be the result of an ascend-
ing infection from the bladder to the kidney. However, this
widely accepted paradigm does not adequately address ques-
tions raised by epidemiologic data. Why does an initial UTI
predispose a woman to an increased likelihood of a recurrent
infection? Why are up to 68% of rUTIs caused by E. coli
identical to the original infecting strain (23)? Why are recur-
rent uropathogens not more representative of the diversity of
E. coli isolates present within an individual’s gastrointestinal
tract (2, 21)?
Although it is believed that bladder infection in humans
does not involve the bladder wall, previous studies of human
bladders indicated a potential intracellular component of UTI
(3). Cultures of bladder biopsies taken from women with ster-
ile urine cultures with various urinary tract symptoms revealed
the presence of bacteria. Studies of mice have revealed that
bacterial invasion of the epithelium lining the bladder lumen
(urothelium) is an essential component of lower UTI.
In mice, adhesive bacterial fibers known as type 1 pili are
necessary for invasion into the superficial umbrella cells of the
urothelium (17, 18). Entry into these host cells initiates a
program that has been extensively characterized in mice using
the human cystitis isolate UTI89 and that results in the forma-
tion of intracellular bacterial communities (IBCs). Early IBCs
are seen within 6 h of infection and consist of loosely packed
rod-shaped bacteria (19). Over the next 6 h, they expand into
tightly packed consortia of coccoid-shaped bacteria (mid-IBC)
(15). Sixteen hours after infection, bacteria detach from the
late IBC, elongate into a filamentous form, escape from the
host epithelial cell, and spread in the bladder to reinitiate
the IBC cascade in other host superficial umbrella cells (15,
19). Subsequent rounds of IBC formation allow E. coli cells to
build up large populations within the bladder. Interestingly,
within 12 h of infection, virtually all bacteria in the bladder are
intracellular, implying that luminal bacteria are rapidly elimi-
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nated (18). One consequence of bacterial invasion is the es-
tablishment of a quiescent intracellular reservoir (QIR) in the
bladder that can persist for months even in the face of antibi-
otic therapy (25). In addition, bacteria in this QIR can revert to
an active metabolic state that is initiated by unknown signals:
rapid intracellular bacterial replication ensues, reinitiating ad-
ditional rounds of IBC formation, inflammation, and spread of
bacterial infection throughout the urinary tract (20). This
model argues that a portion of rUTIs in humans could be
seeded from bacteria present in a QIR in the bladder.
In this study, we investigated the ability of multiple clinical
isolates to form IBCs in the mouse model. We found that (i)
the majority of UPEC isolates proceed through the IBC path-
way; (ii) although isolates from women with ASB, acute UTI,
rUTI, and pyelonephritis all form IBCs, IBCs from acute UTI
isolates are significantly smaller; and (iii) isolates unable to
from IBCs alone are able to do so in mixed infections where
the second isolate was an IBC-competent strain. Together,
these results confirm that the ability to form IBCs is a common
attribute of UPEC isolates.
MATERIALS AND METHODS
Patients and strains. Clinical studies were approved by the University of
Washington Institutional Review Board, and written informed consent was ob-
tained from all participants.
Five isolates causing ASB and four isolates causing first-episode acute cystitis
(acute UTI) were collected from women enrolled in a previously described study
at the University of Washington (5). Briefly, healthy women between 18 and 40
years old who were about to start or had started a new method of contraception
and who had no more than one UTI in the previous year were eligible for
enrollment. The study excluded a woman if she was pregnant, planned to become
pregnant, had a chronic illness, had used systemic antimicrobial agents within 14
days, or had a known anatomical or functional abnormality of the urinary tract.
Enrollees were monitored for 6 months, during which time urine was collected at
monthly clinic visits and whenever patients had symptoms suggestive of a UTI.
Asymptomatic bacteriuria was defined as 105 CFU of a uropathogen per
milliliter of midstream urine documented in at least two separate cultures ob-
tained at least 24 h apart. A symptomatic, culture-confirmed episode of cystitis
was defined as 102 CFU of a uropathogen per milliliter of midstream urine
from a patient with dysuria, frequency, and/or urgency.
E. coli isolates from five women with recurrent cystitis were collected from
another study of healthy women between 18 and 45 years of age who had acute
cystitis and a history of at least one previous UTI in the past year, who were not
pregnant and did not plan to become pregnant, and who had no chronic health
problems (T. M. Hooton, unpublished data). Approximately 110 women have
been enrolled in this ongoing prospective study investigating the temporal asso-
ciations between bacteriuria and clinical manifestations of recurrent UTI. The
women were treated and then monitored by using daily urine cultures for 3
months, during which time they were seen in the clinic on a regular basis and
whenever they had symptoms suggestive of a UTI. rUTI isolates used in that
study were the initial isolate from women with “same-strain” recurrence. “Same-
strain” isolates were identified by chromosomal restriction fragment length poly-
morphism analysis using pulsed-field gel electrophoresis (23).
E. coli isolates collected from four women between 18 and 45 years of age who
had a clinical diagnosis of pyelonephritis were also included in our analysis
(T. M. Hooton and W. E. Stamm, unpublished data). Women were eligible for
this study if they had fever, back pain and/or costovertebral angle tenderness
(CVAT), and a positive urine culture, as defined above.
Virulence factor PCR. Bacterial chromosomal DNA was isolated from each
UPEC strain after growth overnight in Luria broth (LB) by using the Wizard
genomic DNA purification kit (Promega). PCRs to detect virulence factors were
performed as described previously by Johnson and Stell (14).
Western blotting for detecting PapA and FimH proteins. For immunoblot
analysis to detect the PapA protein in the pyelonephritis isolates, bacteria were
grown on tryptic soy agar plates at 37°C for 36 h, scraped, and suspended into 1
ml of phosphate-buffered saline (PBS). Resuspended cells were heated at 65°C
to remove bound pili (9), and the supernatants containing pili were heated in
sodium dodecyl sulfate (SDS) sample buffer (0.25 M Tris-HCl [pH 6.8], 4% SDS,
20% glycerol, 50 mM dithiothreitol, bromophenol blue)–4 M urea at 95°C and
analyzed by SDS-polyacrylamide gel electrophoresis followed by immunoblotting
with antibodies to the P pilus (11).
For immunoblot analysis of FimH expression, bacteria were grown statically in
LB at 37°C for 24 h. Equivalent numbers of cells (optical density at 600 nm of
1.0) from each isolate were suspended in SDS sample buffer, 1 M HCl was
added dropwise until a pH indicator (bromophenol blue) turned yellow, and
solution was heated at 95°C for 5 min. The samples were then neutralized and
analyzed by SDS-polyacrylamide gel electrophoresis followed by immunoblotting
with antibodies to FimH (raised in rabbits using purified FimH protein). Specific
FimH proteins were visualized on nitrocellulose membranes by using the BCIP/
NBT liquid substrate system (Sigma) and analyzed for intensity using ImageJ
software (http://rsb.info.nih.gov/ij/).
HA assays for detecting bacterial adhesins. Bacteria were grown statically in
LB for 24 h to induce expression of type 1 pili. Hemagglutination (HA) assays
with guinea pig erythrocytes were performed using well-established protocols
(10, 26).
Mouse strains and infections. All studies using mice were approved by the
Animal Studies Committee of Washington University. Eight-week-old female
mice belonging to the inbred C3H/HeN strain were anesthetized and inoculated
with a 50-l suspension of 107 CFU of a given clinical isolate (in PBS) via
transurethral catheterization (19). Three, 6, 12, 16, and/or 24 h after inoculation,
animals were euthanized, and their bladders harvested, divided in half, opened,
and pinned onto dissecting wax. Bladders were washed three times with PBS to
eliminate loosely associated bacteria not likely involved in infection. The splayed
bladders were then incubated for 20 min at room temperature with (i) wheat
germ agglutinin (WGA) (1:1,000 in PBS; Molecular Probes) to stain their lumi-
nal surfaces and (ii) SYTO 61 red (1:1,000 in PBS; Molecular Probes) to stain
IBCs as well as host urothelial cell nuclei. (Individual bacteria could be visualized
in the densely packed IBCs, thus distinguishing them from the nuclei.) Trolox (10
M; Fluka) was added to the splayed bladders to reduce photobleaching (24).
The total number of IBCs was scored by confocal microscopy (see below). If all
infections were not successful, five successfully infected mice were used for
further evaluation. The diameters of a maximum of 25 IBCs (five IBCs/bladder/
isolate [n 5 bladders/isolate]) were measured across the width of each IBC and
averaged, and standard deviations were calculated to estimate differences in the
sizes of IBCs. If less than 25 IBCs were observed for a given isolate, the total
number of IBCs observed was used to calculate the average diameter and stan-
dard deviation. If IBCs were not observed in all five bladders inoculated with
a clinical isolate, more than five IBCs were measured per bladder containing
IBCs to obtain 25 measurements. After microscopy, bladders were homoge-
nized in 1 ml of 0.025% Triton X-100–PBS, and bacterial titers were deter-
mined by plating serial dilutions of the homogenates onto LB agar plates.
Standard gentamicin assays were done to define the number of intracellular
bacteria in the bladder (19).
For single infections with the two laboratory strains, strains UTI89 and
CFT073 were genetically engineered to express green fluorescent protein (GFP).
Eight-week-old female mice belonging to inbred C3H/HeN, C3H/HeJ, C57BL/
6J, CBA/J, and FVB/NJ strains were inoculated with UTI89-GFP and CFT073-
GFP as described above. At 6 and 24 h after inoculation, bladders were harvested
as described above; however, the splayed bladders were fixed and visualized
without additional staining due to GFP-expressing UTI89 and CFT073.
Coinoculation of clinical isolate and UTI89. Equal amounts of each clinical
isolate and UTI89-GFP (cystitis strain engineered to express GFP) were mixed
to obtain a 50-l bacterial suspension of 107 CFU. The suspension was then
inoculated into C3H/HeN mice, and infected bladders were harvested and visu-
alized as described above. UTI89-gfp contains the kanamycin resistance cassette
and is thus Kanr, whereas the clinical isolate was Kans. Serially diluted bladder
homogenates were plated onto LB agar plates and LB agar plates containing
kanamycin (50 g/ml) and grown overnight at 37°C. The number of CFU of the
clinical isolate was determined by subtracting the number of kanamycin-resistant
CFU of strain UTI89 from the total number of CFU on LB medium lacking
kanamycin.
Confocal scanning laser microscopy. Bladders were examined with a Zeiss
LSM410 confocal laser scanning microscope under a 63 objective. WGA and
SYTO 61 were excited at 488 and 633 nm, respectively. In coinoculation exper-
iments using GFP-expressing UTI89 and a clinical isolate that did not form IBCs
alone, GFP was excited at 488 nm, the clinical isolate was stained red by SYTO
61, and wheat germ agglutinin was omitted.
Statistical analysis. Observed differences in IBC diameters between isolates
representing the four different types of UTI were analyzed for significance using
the nonparametric Mann-Whitney U test (InStat; GraphPad Software).
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Virulence genotypes of the clinical isolates. We studied 18
clinical isolates collected from women enrolled in the three
different studies described above (Table 1). To characterize
the isolates, they were first analyzed in vitro for the presence of
29 putative virulence factors by multiplex PCR, as previously
described (14). The level of type 1 pilus expression was then
assessed with hemagglutination assays and immunoblotting us-
ing FimH antisera. The isolates were then analyzed in a murine
model to assess their ability to form IBCs within the bladder.
UPEC virulence factors are typically involved in the coloni-
zation and invasion of the host and evasion of the immune
responses. Each isolate had a unique combination of virulence
factors, and their prevalence was similar to that reported in a
previous study that analyzed 63 UPEC isolates (13), suggesting
that our small sample size was representative of a larger, di-
verse UPEC group (Table 2). The most prevalent virulence
factors were fimH (100% of isolates), fyuA (yersiniabactin re-
ceptor; 80%), traT (serum resistance; 70%), the pathogenicity-
associated island marker (CFT073 pathogenicity-associated is-
land marker for a series of genes that provide a mechanism for
horizontal transfer of virulence factor genes; 70%), kpsMTII
(group 2 capsule; 70%), sfa/focDE (S/F1 fimbriae; 60%), and
hlyA (hemolysin; 50%). The presence or absence of individual
virulence factors could not be correlated with a particular
clinical syndrome.
Surprisingly, none of the four pyelonephritis isolates had
genes within the pap operon, which codes for the production of
P pili. Due to the absence of the pap operon, anti-P-pilus
antibodies failed to react with these isolates after growth on
tryptic soy agar, which typically induces the production of P pili
(Fig. 1).
Type 1 pilus production in clinical isolates. HA of guinea
pig red blood cells was performed as previously described (10)
to determine the degree of type 1 pilus production by each
clinical isolate. Type 1-mediated HA is specifically inhibited by
the addition of exogenous mannose, and this reaction is re-
ferred to as mannose-sensitive HA (MSHA).
For this study, bacteria were grown in static culture at 37°C
for 24 h to enhance type 1 production. After 24 h of static
growth, UTI89, a prototypic cystitis reference strain that was
shown to proceed through the IBC pathway, produced an
MSHA titer of 64 (values equal 2x, where x equals the last well
of agglutination). Comparable MSHA titers were seen with the
ASB isolates, which ranged from 32 to 128, suggesting a level
of type 1 production similar to that of strain UTI89 (Table 2).
The first-event UTI strains (acute UTI isolates) produced
MSHA titers ranging from 16 to 64. The rUTI isolates had HA
titers ranging from 2 to 8 that could not be entirely inhibited by
the addition of exogenous mannose. The persisting HA titers
in the presence of mannose suggests the expression of a man-
nose-resistant adhesin system under these growth conditions.
The pyelonephritis isolates had mannose-resistant HA
(MRHA) titers ranging from 4 to 16.
To further confirm the results seen with HA titers, anti-
FimH antibodies were used in immunoblot assays to assess the


















ASB1 PUTS 24 ASB None NA NA 0 39 W/sep/15
ASB2 PUTS 24 ASB None NA NA 0 22 W/NM/16
ASB3 PUTS 24 ASB None NA NA 0 21 W/NM/13–15
ASB4 PUTS 20 ASB None NA NA 0 28 W/div/13–15
ASB5 PUTS 16 ASB None NA NA 0 18 W/NM/12
Acute1 PUTS 24 First event D, F, H NR NA 0 23 W/NM/17
Acute2 PUTS 24 First event D, F, H NR NA 0 23 W/NM/17
Acute3 PUTS 25 First event D, U 4 NA 0 19 W/NM/12
Acute4 PUTS 24 First event F, U, N 1 NA 0 18 Hisp/NM/12
rUTI1 TOP 12 Recurrent D, F 1 23 5 27 W/NM/17
rUTI2 TOP 12 Recurrent D, F 1 13 10 25 W/NM/17
rUTI3 TOP 12 Recurrent D, F 2 18 3 22 A/NM/13–15
rUTI4 TOP 12 Recurrent D, F, U 2 19 1 21 A/NM/12
rUTI5 TOP 12 Recurrent D, F, U 1 6 20 23 W/NM/13–15
Pyelo1 Pyelo 20 Pyelonephritis F, N, S, O, LBP,
FE, C
16 19 3 21 W/NM/15
Pyelo2 Pyelo 4 Pyelonephritis D, F, U, N, S, O,
LBP, FE, C
1 24 3 24 Other/NM/18
Pyelo3 Pyelo 16 Pyelonephritis D, F, U, N, S, LBP,
FE, LAP
3 19 1 25 W/div/21
Pyelo4 Pyelo 4 Pyelonephritis U, LBP, FE, C,
LAP, I
2 NA 0 20 Other/NM/13
a Abbreviations: D, dysuria; F, frequency; H, hematuria; U, urgency; N, nocturia; S, urinating in small amounts; O, urine odor; LBP, lower back pain; FE, fever; C,
chills; LAP, lower abdominal pain; I, incontinence; NA, not applicable; NR, not recorded; W, white; Hisp, Hispanic; A, Asian; sep, separated; NM, not married; div,
divorced.
b Enrollment criteria were as follows: for predisposition to UTI study (PUTS), women aged 18 to 40 years starting a new birth control method (may be pill, diaphragm,
cervical cap, or foam and condoms) with no history of more than one UTI in the past year; for transcience of pathogens (TOP), women aged 18 to 45 years who were
not pregnant, were taking contraception, had symptoms for less than 7 days, had no chronic health problems, and had no CVAT; for pyelonephritis study (Pyelo),
women aged 18 to 45 years with a clinical diagnosis of pyelonephritis with fever, back pain, and/or CVAT.
c Race/marital status/years of education.
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relative levels of FimH in all of the strains after 24 h of growth
in static broth. The intensity of each band was quantitated and
expressed as a value relative to the amount of FimH expressed
by UTI89, which was set at 100% (Table 2). MC4100, which
does not produce type 1 pili, was used as a negative control.
The majority of isolates expressed type 1 pili at levels of 50%
to 99% of the levels expressed by strain UTI89. Only one
isolate, ASB3, expressed type 1 pili at a level substantially
higher than that of UTI89, 150% to 199%. Strains acute1,
rUTI1, and rUTI4 did not express detectable levels of type 1
pili, and acute3 and CFT073 expressed comparable levels of
type 1 pili relative to that of UTI89 as determined by our
immunoblot analysis. These results suggest that UPEC isolates
from different clinical syndromes produce various degrees of
type 1 pili in vitro.
IBC formation by UPEC strains isolated from women. First,
the commonality of the IBC pathway in the face of differing
host responses was evaluated. To date, the IBC pathway has
been best described using the C3H/HeN and C3H/HeJ mouse
strains with UPEC strains UTI89 and NU14 (1, 15, 18). A
previous study evaluated the level of infection and inflamma-
tion in different mouse genetic backgrounds but did not exam-
ine the IBC pathway (8). To determine whether the cystitis and
pyelonephritis isolates UTI89 and CFT073, respectively, form
IBCs in various host genetic backgrounds, three other mouse
strains were infected, C57BL/6J, CBA/J, and FVB/NJ. Mouse
strains for use in this study were chosen based on their previ-
ous use as models for host responses to UPEC infection and/or
identification of bacterial virulence factors (16, 18, 27). At 6 h
postinfection, IBCs were detected in all mouse strains tested
with both UPEC strains. IBCs from C3H/HeJ (Fig. 2D and I)
and C3H/HeN (Fig. 2E and J) mice showed the expected IBC
morphology inside superficial epithelial cells. Early IBCs were
readily detected in C57BL/6J, CBA/J, and FVB/NJ (Fig. 2A to




immunoblotcpapACEFG sfa/focDE fimH hlyA fyuA iutA kpsMTII kpsMTIII K1 K5 ibeA traT PAIa HAb HAmannose
ASB1              128 2 
ASB2              64 2 
ASB3              128 2 
ASB4              32 2 
ASB5              128 2 
Acute1              16 2 0
Acute2              64 2 
Acute3              64 2 
Acute4              32 2 
rUTI1              8 8 0
rUTI2              2 2 
rUTI3              8 2 
rUTI4              2 2 0
rUTI5              8 4 
Pyelo1              16 16 
Pyelo2              4 2 
Pyelo3              8 8 
Pyelo4              8 8 
UTI89              64 2 
CFT073              128 4 
% Prevalence 40 60 100 50 80 40 70 10 20 45 25 70 70
a PAI, pathogenicity-associated island marker.
b HA, hemagglutination of guinea pig red blood cells. Values equal 2x, where x equals the last well of agglutination.
c Percent expression relative to UTI89 (0  0% to 49%;   50% to 99%;   100% to 149%;   150% to 199%).
FIG. 1. Immunoblot of pyelonephritis isolates with antibodies
against P pili. P pilus antibodies were raised against J96 P pili; thus, J96
and UTI89 were used as positive controls for P pilus production. Both
isolates are positive for P pili due to a PapA-specific band at a molec-
ular weight of 16,500 (16.5K). However, the P pilus antibody did not
recognize the 16.5K protein for the four pyelonephritis isolates, con-
firming the lack of the pap operon seen with multiplex PCR. Thus,
pyelo1, pyelo2, pyelo3, and pyelo4 do not contain the genes, nor do
they produce protein associated with P pili, which are thought to be
critical in kidney colonization.
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C and F to H) mice, which were visually indistinguishable from
IBCs in the C3H genetic background. Occasionally, some IBCs
in C57BL/6J mice had more loosely defined edges. The pres-
ence of IBCs at 6 h postinfection in five mouse strains after
infection with UTI89 and CFT073 suggests that the mecha-
nisms utilized for invasion and intracellular replication in vivo
are a conserved feature in these strains.
Next, the commonality of IBC formation among different
clinical isolates was evaluated. Eighteen clinical isolates re-
covered from women enrolled in three different UTI studies
(Table 1) were evaluated for their ability to form IBCs. Each
isolate was inoculated transurethrally into the bladders of
young adult female C3H/HeN mice, and the bladders were
harvested at 3, 6, 12, 16, and 24 h postinfection (n  5 mice/
time point/isolate) (Table 3 and Fig. 3).
All five ASB isolates formed IBCs, although the time course
varied: IBCs were observed 6 h and 24 h after inoculation of
strains ASB1, ASB2, and ASB3 (Fig. 3E and F), while IBCs
were observed only at 6 h for ASB4 and at 24 h for ASB5. This
suggests that although IBC formation is common, the rate at
which the isolates proceed through the pathway is potentially
strain specific. In UTI89, first-round IBCs were observed at 6 h
postinfection and second-round IBCs were observed at 24 h
postinfection despite asynchronous micturation among the
mice. Since IBCs were not observed at 24 h in strain ASB4, it
is possible that the second-round IBCs were either earlier or
later and thus missed. The fact that ASB5 formed apparent
IBCs only at 24 h postinoculation suggests that it either pro-
ceeds more slowly through the IBC pathway due to slow rep-
lication within the umbrella cells or invades the urothelium at
later time points. ASB5 produces a high MSHA titer (128),
and FimH was detectable in the immunoblots (Table 2). These
piliation characteristics strongly argue that the observed delay
in IBC formation is not related to type 1 pilus expression in the
inoculum. The average diameter of ASB IBCs was 51	 20 m
(five IBCs/bladder), which is the same as that of the prototypic
isolate, UTI89, which has an average IBC diameter of 51 	 9
m at 6 h postinfection.
Three of the four acute UTI isolates formed IBCs at the
time points examined. Again, there were isolate-specific dif-
ferences in the time course. IBCs were observed only at 3 h in
acute3 (Fig. 3B), 6 h in acute2, and 12 h in acute1 (data not
shown) (n  5 mice for each group). IBCs in all acute UTI
isolates were small, with an average diameter of 20 	 8 m
(P  0.01 compared to UTI89 and ASB isolates) and sparse
(average of 3 IBCs/bladder compared to 20 to 100 IBCs/
bladder with UTI89 and ASB isolates [n  15 mice]). No IBCs
were observed at any of the five time points surveyed for
acute4. However, bacteria were visualized on the luminal sur-
face of the bladder and quantitated by tissue titer to be greater
than 102 CFU/bladder throughout the time course. With
UTI89, by 12 h, virtually all of the bacteria entered an intra-
cellular niche (19). The ability of acute4 to persist extracellu-
larly up to 24 h emphasizes that different UTI strains may use
alternative mechanisms to cause infection. Although acute4
produces type 1 pili in vitro, it is unable to form IBCs. Thus,
additional factors must be critical for IBC formation indepen-
dent of type 1 piliation. Acute4 was further analyzed in studies
described below and in separate studies to investigate the
mechanism by which it persists in the urinary tract.
IBCs were observed for four of the five recurrent cystitis
isolates. IBCs were observed only at 3 h in rUTI5 (Fig. 3A), 6 h
FIG. 2. UTI89 and CFT073 formed IBCs in multiple mouse strains. UTI89 and CFT073, two commonly used UTI isolates, were inoculated into
five different mouse strains. At 6 h postinfection, each mouse strain was able to support IBC formation by each UTI isolate. A to E represent UTI89
IBCs, and F to J represent CFT073 IBCs.
TABLE 3. IBC formation at different time points
Isolate type
No. of IBC-forming isolates/total no. of isolatesa
3 h 6 h 24 h No IBCs Avg IBC diameter(m)
ASB 0/5 4/5 4/5 0/5 51	 20
Acute 1/4 1/4 0/4 1/4 20	 8
Recurrent 1/5 2/5 1/5 1/5 41	 14
Pyelonephritis 0/4 3/4 0/4 1/4 55	 10
a n  5 mice/time point. Five IBCs/bladder/isolate were measured (n  5
bladders).
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in rUTI2 (Fig. 3C) and rUTI3, and 24 h in rUTI4 (n  5 mice
for each group), again showing differences in the IBC pathway.
The diameter of the IBCs observed in all four isolates was 41	
14 m, a value that is significantly greater than those of acute
UTI strain IBCs (P  0.05) but not significantly different from
those of UTI89 or ASB strain IBCs (P  0.274). Similar to
strain acute4, rUTI1 bacteria were present in the bladders
throughout the time course, as evidenced by tissue titers (103
to 104), but no IBCs were observed by microscopy. However, in
contrast to acute4, rUTI1 expressed little to no type 1 pili in
vitro (Table 2) even though it contains the fimH gene. The
inability to produce type 1 pili in vitro could possibly explain
the inability of rUTI1 to invade (see below) and form IBCs at
the time points tested. Whether type 1 pilus expression can be
induced in vivo at later time points and lead to invasion and
IBC formation will be the subject of future studies.
Of the four pyelonephritis isolates, three formed IBCs and
did so by 6 h postinoculation (Fig. 3D), suggesting similar
kinetics in their IBC pathways (n 5 mice in each group). The
IBC diameter (55 	 10 m) was significantly larger than that
for acute UTI strains (P  0.01). IBCs were not observed with
pyelo3, and, similar to rUTI1, MSHA was not detected after
growth in static broth in vitro (Table 2). As seen with the two
other strains that were unable to form IBCs, acute4 and rUTI1,
pyelo3 was unable to invade into the superficial umbrella cells
of the bladder (see below).
Invasion defects in strains unable to form IBCs. Since in-
vasion is a prerequisite for IBC formation, we performed an in
vivo gentamicin protection assay to assess whether any of the
three isolates that did not form IBCs, acute4, rUTI1, and
pyelo3, had invasion defects. PCR demonstrated that the fimH
gene was present in all three strains, and HA assays revealed
that acute4 produced type 1 pili, while rUTI1 and pyelo3 pro-
duced mannose-resistant fibers. The ability of UPEC to invade
is thought to be dependent on type 1 pili (17). At 1 h postin-
fection, bladders were removed, bisected, and incubated in
gentamicin to kill extracellular bacteria. Homogenates of the
treated bladders were then cultured, since intracellular bacte-
ria have been shown to survive this treatment (19). Bacterial
titers revealed that the three non-IBC-forming isolates were
deficient in invasion compared to UTI89 (Fig. 4). A total of
4.4% of adherent UTI89 bacteria (defined as bacteria removed
from the lumen after multiple washes) were able to invade the
urothelium (defined as bacteria surviving the gentamicin treat-
ment). In contrast, the three isolates that did not form IBCs
(acute4, rUTI1, and pyelo3) had invasion percentages of 0.3%,
FIG. 3. IBCs were formed by UPEC strains isolated from women. Clinical isolates (red) were inoculated into female C3H/HeN mice, and
bladders were harvested at 3 h, 6 h, and 24 h. Fifteen isolates produced IBCs at either (A and B) 3 h, (C and D) 6 h, or (E and F) 24 h. Each clinical
syndrome is represented at the top of each panel. The cell surface (green) was stained with WGA and can be seen bordering the umbrella cells
in this cross-sectional view. While the majority of isolates produced IBCs, the sizes and densities of the IBCs varied. Bars, 10 m.
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0.5%, and 1.1%, respectively, thus potentially explaining their
inability to form IBCs.
Mixed-infection model of UTI89 with a non-IBC-forming
isolate. Due to the complex nature of the intestinal, perianal,
vaginal, and periurethral microbiota, it is likely that the initial
inoculum in the human bladder is a mixture of bacterial strains.
We sought to investigate whether one isolate could improve
the fitness or outcompete another isolate in the bladder. Thus,
we investigated the outcome of experiments where UTI89 was
genetically engineered to express a readily detectable green
fluorescent protein marker and then coinoculated with each of
the three non-IBC-forming clinical isolates in equal concen-
trations. Although IBCs were not observed during single in-
fections with acute4, when it was coinoculated with UTI89,
acute4 was able to participate in IBC formation but only as a
mixed IBC with UTI89-GFP IBCs (Fig. 5C and D). When
rUTI1 was coinfected with UTI89, rUTI1 formed IBCs at 24 h
(Fig. 5B) and caused UTI89 to form giant IBCs at 6 h (diam-
eter, 130 	 25 m) (Fig. 5A). Pyelo3 was unable to form IBCs
in the presence or absence of UTI89 and even prevented IBC
formation in UTI89. In the UTI89/pyelo3 mixed infection,
most of the extracellular (luminal) pyelo3 cells were filamen-
tous, and this same overwhelming filamentation phenotype was
induced in UTI89 (Fig. 5E and F). Interestingly, although two
FIG. 4. The three non-IBC-forming isolates, rUTI1, acute4, and
pyelo3, were deficient in invasion in vivo. Female C3H/HeN mice were
inoculated with UTI89, rUTI1, acute4, and pyelo3. At 1 h postinfec-
tion, bladders were removed and processed. The luminal fraction rep-
resents luminal bacteria, and the intracellular fraction represents in-
vaded bacteria. One hour after inoculation, 4.4% of UTI89 bacteria
invaded, whereas for rUTI1, acute4, and pyelo3, only 0.3%, 0.5%, and
1.1% of luminal bacteria invaded, respectively. Thus, the three non-
IBC-forming isolates invade poorly relative to UTI89.
FIG. 5. Coinfection with a clinical isolate and UTI89 altered the behavior of the bacteria. (A and B) rUTI1 (red) produced IBCs only when
coinfected with UTI89 (green) and caused UTI89 to produce abnormally large IBCs (compare A to C). (C and D) acute4 (red) formed mixed IBCs
with UTI89 (green), which also formed normal IBCs. (E and F) pyelo3 (red) formed large collections of filaments, induced UTI89 (green) to do
the same, and prevented UTI89 IBCs. Bars, 10 m.
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of the three clinical isolates altered the behavior of UTI89,
they were present in the bladder in quantities that were 100- to
1,000-fold less than UTI89 at each time point tested (n  5
mice in each group). Additionally, all three of the clinical
isolates showed altered behavior in the presence of UTI89
relative to their behavior when inoculated individually. Clini-
cally, a UTI is often defined as bacteria in the urine in quan-
tities greater than 105, and mixed infections with different
UPEC strains would typically not be detected. Thus, small
amounts of a competing strain in the bladder could possibly
have profound and distinct effects on the outcome of infection.
DISCUSSION
The widely accepted paradigm of acute and recurrent infec-
tion is that both types of infection are due to the ascension of
bacteria from the gut microbiota to the vagina and then the
bladder. In addition, UTIs have clinically been thought to be
due to simple extracellular colonization of the urothelium by
UPEC. However, it has recently been shown that UPEC in-
vades the urothelium in order to subvert innate defenses in
mice (15, 17, 18). Likewise, intracellular bacteria have been
found in the human bladder following UTI (3). The discovery
and characterization of IBCs in the murine model of cystitis
has challenged the traditional clinical paradigm of UTIs and
revealed a mechanism by which UPEC isolates are able to
build up in numbers in the bladder despite potent innate de-
fenses. The IBC pathway has been well characterized with the
cystitis isolate UTI89 in the C3H mouse model of cystitis. In
this study, we have demonstrated that the IBC pathway is
common to most UPEC strains isolated from humans with
different UTI syndromes and from mice of different genetic
backgrounds.
We found, through multiplex PCR virulence factor assays,
that the isolates chosen for this study were representative of a
larger pool of UPEC isolates (13). Surprisingly, none of our
pyelonephritis isolates contained any genes within the pap
operon and thus did not express P pili. The pap operon codes
for P pili containing a distally located PapG adhesin that binds
the globoside receptor in the human kidney, which has been
shown to be critical for the ability of pyelonephritic strains to
colonize the kidney (22). The four pyelonephritis strains in this
study were obtained from patients that had classic symptoms of
pyelonephritis, namely, fever and CVAT (Table 1). The ab-
sence of the pap operon in these strains is intriguing, but given
the small sample size, further studies will need to be done to
interpret the significance of this finding. In contrast, all of the
pyelonephritis isolates, as well as the ASB, acute UTI, and
rUTI isolates, had the fimH gene. However, expression of type
1 pili after growth in static LB differed among the strains.
Strains with various levels of type 1 pili after in vitro growth
were able to colonize the mouse bladder and form IBCs. It is
possible that the in vivo environment in the bladder altered the
type 1 pilus expression profile after inoculation, thus partially
explaining the ability of strains with various levels of type 1 pili
to colonize and form IBCs within the bladder.
In our mouse model of UTI, we demonstrated that 15 of 18
clinical isolates from various human clinical syndromes pro-
ceeded through the IBC pathway when inoculated as a single
strain. However, IBC formation differed among the strains in
terms of the kinetics by which bacterial communities formed,
the size of the communities, and the number of communities.
While isolates from each clinical syndrome formed IBCs, the
acute UTI isolates formed significantly smaller and fewer IBCs
relative to any other syndrome. In general, ASB, rUTI, and
pyelonephritis strains are associated with longer-term persis-
tence in the host. The ASB, rUTI, and pyelonephritis strains
produced more IBCs/bladder, and the IBCs were of increased
size compared to acute UTI strains. The differences in IBC
behaviors of the acute strains compared to those of the other
three groups could potentially explain why the acute strains are
less persistent.
The behaviors of the three outlying strains (rUTI1, acute4,
and pyelo3) required more research to better understand their
apparent deviations in IBC behavior with respect to their
group. rUTI1, acute4, and pyelo3 were unable to efficiently
invade the superficial umbrella cells of the bladder and were
thus unable to form IBCs. The lack of IBC formation in the
three isolates could not be associated with a specific virulence
factor due to their differing virulence factor profiles. Likely,
there is a multitude of virulence factors contributing to IBC
formation and perhaps some redundancy in the necessary fac-
tors. rUTI1 did not produce any detectable levels of type 1 pili
in vitro, which thus most likely explains its inability to invade
and form IBCs at the time points tested. Acute4 was able to
produce type 1 pili in vitro at levels equivalent to or better than
those of isolates that were able to form IBCs, suggesting that
type 1 pilus expression is not sufficient for IBC formation and
implicating the importance of other factors in invasion. Pyelo3
produced a small amount of type 1 pili as determined by
immunoblotting with anti-FimH antisera. No MSHA was de-
tected in vitro, possibly because of the presence of MRHA
adhesins that would potentially mask type 1 pilus-mediated
hemagglutination. The deficiency of in vivo invasion of pyelo3
could suggest that the MRHA adhesins somehow interfered
with the process and/or that pyelo3 lacked other factors in-
volved in invasion.
Given the diverse microbial communities in the rectum and
vagina (2, 21), it is likely that multiple strains of bacteria are
simultaneously introduced into the urinary tract of a woman
during the early events that lead to a UTI, such as sexual
intercourse. While mixed infections may select for bacteria
with a distinct competitive advantage, they may also allow less
virulent bacteria the opportunity to establish a niche in con-
junction with more efficient UPEC strains. Coinoculation of
UTI89, a known IBC-forming strain, with each of the three
isolates that were deficient in IBC formation resulted in dra-
matic, synergistic effects. Of the three isolates for which IBC
formation was not detected, two were able to do so in mixed
infections with UTI89 (rUTI1 and acute4). This may explain
the seemingly outlying behavior of these strains when analyzed
in single infections. The diagnosis of UTIs rarely delineates
whether multiple strains of E. coli are present. Thus, strains
such as rUTI1 and acute4 could have “piggy-backed” with a
more invasive IBC-forming strain that went undetected. UTI89
formed significantly larger IBCs in the presence of rUTI1. This
may be due to potential host responses induced by rUTI1 that
facilitate bacterial replication in the superficial umbrella cells,
or possibly, rUTI1 induces signals that prevent or slow the
dispersal and fluxing of the bacteria in the IBC. IBC formation
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is a clonal process in that each IBC arises from a single bac-
terium (P. C. Seed and S. J. Hultgren, unpublished data).
Surprisingly, the mixed infection with acute4 and UTI89 re-
sulted in nonclonal IBCs. Acute4 existed as a mixed IBC only
with UTI89. The bacteria did not intermingle in the IBC, but
instead, each strain seemed to group together in patches that
melded into one IBC. These results argue that UTI89 was able
to provide factors in trans that could support acute4 in the
intracellular biofilm matrix.
Pyelo3 was the only strain in our study that was unable to
form IBCs under any of the conditions tested. Coinoculation of
UTI89 and pyelo3 resulted in massive filamentation of both
isolates. Based on previous work showing that filamentation
occurs in response to an inflammatory response (15), further
study is required to assess whether pyelo3 is triggering a more
robust innate response that leads to the massive filamentation
observed. The complexities that we have observed with coin-
fections between the bacteria and with the host might explain
the occurrence of different clinical syndromes manifested by
the same organism (6) or the differing behavior in single versus
mixed infections as described above. Alternatively, it is possi-
ble that these isolates could represent a class of strains that do
not use the IBC pathway but instead use a different extracel-
lular strategy for persistence.
In summary, 15 of 18 isolates causing different clinical syn-
dromes in humans and possessing various combinations of
virulence factors were successful in invading the bladder epi-
thelium of mice to form IBCs. Two of the remaining three
isolates were also able to form IBCs in mixed infections with
UTI89. These findings demonstrate that the IBC pathway is
common to UPEC pathogenesis. Studies are in progress to
determine whether UPEC forms IBCs in humans and whether
they contribute to same-strain recurrences of UTIs. The mu-
rine model of IBC formation will allow investigators to study
the intricacies of host-pathogen interactions in the bladder.
Understanding the basis of the intracellular niche occupied by
UPEC will lead to the better evaluation and treatment of UTIs
and will foster the development of new therapeutic strategies.
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